OncoMatch/Clinical Trials/NCT06280105
A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib
Is NCT06280105 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Cadonilimab+regorafenib for hepatocellular carcinoma.
Treatment: Cadonilimab+regorafenib — To evaluate the efficacy and safety of cadonilimab combined with Regorafenib in patients with hepatocellular carcinoma who failed camrelizumab plus apatinib.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage INTERMEDIATE
intermediate or advanced hepatocellular carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: anti-PD-1 therapy plus VEGFR inhibitor (camrelizumab, apatinib) — combination
Have progressed on the combination treatment of camrelizumab and apatinib for HCC
Cannot have received: liver transplantation
Have a history of liver transplantation
Lab requirements
Blood counts
Neutrophils ≥ 1.5×10^9/L; Platelet count ≥ 75×10^9/L; Hemoglobin ≥ 90g/L
Kidney function
Serum creatinine ≤ 1.5x ULN or creatinine clearance ≥ 50 ml/min (Cockcroft-Gault formula); urine protein < 2+; if urine protein ≥ 2+, 24-hour urine protein quantification ≤ 1g
Liver function
Child-Pugh Class A; Total bilirubin (TBIL) ≤ 3x ULN; AST or ALT ≤ 10x ULN
The function of vital organs meets the following requirements... (see criteria 9 for details)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06280105 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior liver transplantation disqualifies patients from enrollment.
What disease stage is eligible?
Stage INTERMEDIATE is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages